Abstract: The present disclosure provides polypeptides comprising an N-terminal portion(s) of Apolipoprotein B100 (ApoB100), or functional derivatives thereof, particularly polypeptides may be capable of, e.g., inhibiting scavenger receptor-B1 (SR-B1) and/or activin receptor-like kinase 1 (ALK1). Further provided are related polynucleotides, vectors, and pharmaceutical compositions. Methods for blocking endothelial cell uptake and/or transcytosis of lipoproteins comprising chylomicrons, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and/or lipoprotein (a) (Lp(a)) and treating atherosclerosis using the polypeptides and/or pharmaceutical compositions are also provided.

Abstract: Provided are potent miR-30c analogs that can be delivered to hepatoma cells without the aid of viral vectors and lipid emulsions. The miR-30c analogs contain an unmodified active sense strand and a modified passenger strand to enhance the stability and uptake of miR-30c by hepatoma cells. The miR-30c analogs are for use in treatment of hyperlipidemias and cardiovascular diseases.

Abstract: MicroRNAs can be used to decrease expression of apolipoprotein B (apoB), increase expression of apolipoprotein A (apoA), and decrease expression of NCOR1. Use of these microRNAs can simultaneously reduce LDL and increase HDL in circulation and have applications in prevention and treatment of atherosclerosis, hyperlipidemia, and cardiovascular disease as well as other disorders associated with high apoB and/or low apoAI levels.

Abstract: This disclosure provides a novel role for microRNA (miR) regulation of lipid metabolism via the MTP pathway, leading to reductions in apoB secretion and blood lipid levels. MiR regulation of the MTP pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of MTP expression and activity by miR regulation is identified as a new therapeutic target for treatment of cardiovascular disease and conditions or diseases associated with cardiovascular disease such as hyperlipidemia, atherosclerosis, and metabolic syndrome. Treatment of cardiovascular disease and associated conditions or diseases with the novel MTP inhibitors of the invention, such as miR-30c homologs or miR-30c agonists, reduces MTP-associated lipid production without side effects that occur with other methods of MTP inhibition.

Abstract: This disclosure provides a novel role for microRNA (miR) regulation of lipid metabolism via the MTP pathway, leading to reductions in apoB secretion and blood lipid levels. MiR regulation of the MTP pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of MTP expression and activity by miR regulation is identified as a new therapeutic target for treatment of cardiovascular disease and conditions or diseases associated with cardiovascular disease such as hyperlipidemia, atherosclerosis, and metabolic syndrome. Treatment of cardiovascular disease and associated conditions or diseases with the novel MTP inhibitors of the invention, such as miR-30c homologs or miR-30c agonists, reduces MTP-associated lipid production without side effects that occur with other methods of MTP inhibition.

Abstract: This disclosure provides a novel role for microRNA (miR) regulation of lipid metabolism via the MTP pathway, leading to reductions in apoB secretion and blood lipid levels. MiR regulation of the MTP pathway is shown herein to reduce hyperlipidemia and atherosclerosis in vivo. Therefore, inhibition of MTP expression and activity by miR regulation is identified as a new therapeutic target for treatment of cardiovascular disease and conditions or diseases associated with cardiovascular disease such as hyperlipidemia, atherosclerosis, and metabolic syndrome. Treatment of cardiovascular disease and associated conditions or diseases with the novel MTP inhibitors of the invention, such as miR-30c homologs or miR-30c agonists, reduces MTP-associated lipid production without side effects that occur with other methods of MTP inhibition.

Abstract: The present invention is directed to a composition and method for the treatment of hyperlipidemias by targeting Microsomal triglyceride transfer protein (MTP). In particular, the present invention is directed to a combination of at least one MTP inhibitor and at least one lipid-lowering agent, both in an amount effective to treat hyperlipidemias.

Abstract: The present invention is directed to a composition and method for the treatment of hyperlipidemias by targeting Microsomal triglyceride transfer protein (MTP). In particular, the present invention is directed to a combination of at least one MTP inhibitor and at least one lipid-lowering agent, both in an amount effective to treat hyperlipidemias.

Abstract: The invention relates to compositions, medicaments, methods for treating individuals with high plasma lipid levels, and methods for screening drug candidates useful in, for example, the treatment of hypercholesterolemia. Specifically, the invention relates to the discovery that MTP inhibition leads to increased accumulation in cellular free-cholesterol and is useful in the development of compositions, medicaments, methods of treatment and drug screening methods to treat high plasma lipid levels.

Abstract: The present invention is directed to methods for assaying microsomal triglyceride transfer protein (MTP) which are amenable to automation and high throughput screening. The assays may be used to measure MTP activity in cell and tissue homogenates as well as purified MTP. Also provided are methods of measuring levels of lipids transferred by MTP. The methods provided by the present invention have the advantages of ease, rapidity, sensitivity, avoidance of the use of radioactivity, versatility in studying different lipid transfer activities by purified and cellular MTP and the ability to measure inhibitory activity. In addition, methods of identifying compounds that modulate the lipid transfer activity of MTP are provided. Kits for measuring the lipid transfer activity of MTP as well as net transfer of lipid by MTP are provided by the present invention.

Abstract: An advanced intelligent network privacy screening service that allows callers provided with a bypass code to bypass the privacy screening. A termination attempt trigger is provisioned on the subscriber's line at a service switching point. When callers from private or unknown numbers call the subscriber, the call is routed to a service node that plays an announcement to the caller to start the privacy screening process. The caller can then enter the bypass code to bypass the privacy screening. A subscriber to the privacy screening service can change his or her bypass code by calling a system administration number, and entering his or her password and bypass code.

Abstract: Methods of identifying compositions which inhibit lipid and lipoprotein secretion are provided using in vitro assays measuring inhibition of the binding of microsomal triglyceride transfer protein to a specific microsomal triglyceride binding site on apolipoprotein B and lipid complexes.